Pels og skind er in, og bliver hele tiden mere tydeligt i modebilledet. Der tilbydes to forskellige kollektioner  med et bredt udvalg af jakker, frakker, veste, bolero’er m.m. i bedste skind- og pelskvaliteter. Der er lagt vægt på et eksklusivt design, komfort og kreative detaljer. Den unikke AKHESA kollektion er inspireret af det skinnende Middelhav og den farverige Nice. Nøgleordet er livsglæde med den luksus og stil, som hører den franske Riviera til. Det inspirerende design giver kvinder over hele verden mulighed for at udtrykke deres personlighed. Iklædt AKHESA’s troværdige kvalitet og design er de klar til at gå efter deres drømme. KAREN RITZI er Akhesa’s yngre søster, som følger med tiden og tilbyder fashion designs til sprudlende, aktive kvinder, som ikke går på kompromis med deres outfit. En frisk, opsigtsvækkende kollektion, som allerede har alt hvad der kræves af et stort brand. Er du interesseret, så kontakt venligst Annemette Jensen, tlf. 33 37 61 78 for at høre mere.

De 4 internationale modemetropoler Paris, Milano, London og New York har svært ved at blive enige om at lægge datoerne for deres modeuger, så de ikke generer hinanden. Paris, som historisk var den første hovedstad som valgte at arrangere en modeevent og invitere internationale indkøbere og presse, mener at have førsteret til sine datoer, og har derfor meldt ud, at perioden forbliver uændret i 2013 og 2014. Her er datoerne for de næste tre år : A/W 2012/13 : ·          Men’s Fashion – fra onsdag den 18. til søndag den 22. januar 2012 ·          Haute Couture – fra mandag den 23. til torsdag den 26. januar 2012 ·          Prêt à Porter - fra tirsdag den 28. februar til onsdag den 7. marts 2012 S/S 2013 : ·          Men’s Fashion – fra onsdag den 27. juni til søndag den 1. juli 2012 ·          Haute Couture – fra mandag den 2. til torsdag den 5. juli 2012 ·          Prêt à Porter - fra tirsdag den 25. september til onsdag den 3. oktober 2012 NB : de kommercielle modemesser « Prêt-à-Porter Paris/Who’s Next » finder sted den 21. – 24. januar 2012, og den 30. juni – 3. juli 2012 i messecentret Porte de Versailles. Paris Fashion Week 2013 (prêt-à-porter) : 26. februar – 6. marts 24. september – 2. oktober Paris Fashion Week 2014 (prêt-à-porter) : 25. februar – 5. marts 23. september – 1. oktober Hvis du har spørgsmål, er du velkommen til at kontakte Annemette Jensen på tlf. 33 37 61 78

Distributør søges til innovativ teknologi til slankebehandlinger – et effetivt alternativ til fedtsugning og kosmetisk kirurgi Cavitation er en kosmetisk procedure, hvor man ved hjælp af ultralyd får fedtet til at opløses. Lysterapien med rød LED stimulerer produktionen af kollagen, som er ansvarlig for elasticiteten og fastheden af huden. En forøget kollagenproduktion forbedrer fedtforbrændingen, og reducerer desuden ujævnheder i huden. Større områder kan behandles smertefrit og uden risiko for komplikationer på kun 30 minutter. Da kar og nerver ikke beskadiges, opstår der kun meget svag rødmen af huden. Teknikken er afprøvet ved kliniske studier. Apparatet er nemt at bruge, og kræver ingen vedligeholdelse. For mere information, se : SCULPT 3D®    eller kontakt evt. Annemette Jensen, tlf. 33 37 61 78 for yderligere oplysninger.

In Cell Art, a biotechnology company specialising in nanocarrier technologies for macromolecules (including DNA and RNA) and in the development of innovative vaccines and antibodies, has announced today the launch of a US$33.1 million research-and-development project — the RN Armor Vax Consortium. In Cell Art, together with Sanofi Pasteur (the vaccines division of the Sanofi-aventis Group) and CureVac (a German biopharmaceutical firm specialising in mRNA-based vaccinations), has established the consortium which will evaluate new applications of In Cell Art’s technology in the development of mRNA-based vaccines against infectious diseases. Chloé Bellocq, CEO of In Cell Art, comments, “In Cell Art, in its internal projects, as through its collaborative work with the major players in the pharmaceutical sector, is very committed to the development of gene-based vaccines. Our recent results, from the work surrounding treatment and prevention of hepatocellular carcinoma by DNA vaccination, demonstrate the potential of gene-based vaccines in both prophylactic and therapeutic applications.” The RN Armor Vax Consortium collaborative-research project was selected from amongst various proposals submitted following a call for projects entitled Controlling Cellular Machinery, Vaccines. The four-year project has a total budget of US$33.1 million and will be co-funded by the Defense Advanced Research Projects Agency (DARPA, an agency of the United States Department of Defense). The project’s objective is to validate a new universal-vaccine-technology platform that develops and evaluates mRNA-based vaccines (for both prophylactic and therapeutic vaccines against infectious diseases), and which will be the first of its kind. The project will authenticate new applications (such as the elaboration and vectorization of mRNA-based vaccines) of In Cell Art’s nanocarrier technology. It will therefore reinforce the company’s leading position in the nano-transport of macromolecules of DNA and RNA. In parallel with the RN Armor Vax Consortium project, In Cell Art and Sanofi Pasteur signed a non-exclusive option and licence agreement with pre-agreed licence terms. This agreement will enable Sanofi Pasteur to access In Cell Art’s formulation technologies to develop and commercialise mRNA-based vaccines. Under the terms of this agreement, In Cell Art should receive an initial payment, along with milestone payments at certain clinical stages, and royalty payments on the sales of products. In Cell Art will also receive revenue from sales of the clinical and commercial nanocarrier products that will be contained in the final vaccines. Bruno Pitard, co-founder of In Cell Art, explains, “This new agreement demonstrates the importance of our nanocarrier technologies not only for gene-based vaccines that use DNA, but also for mRNA-based vaccines. The project will strengthen the position of In Cell Art as a leading company in the sector and the best choice for the use of nanocarrier technologies to deliver macromolecules DNA and RNA.” About CureVac CureVac is a global leader in mRNA-based vaccination technologies. It develops mRNA-based vaccines as therapeutic vaccines in oncology and prophylactic vaccines for infectious diseases. For further information about CureVac, please go to: www.curevac.com   About The Defense Advanced Research Projects Agency (DARPA) DARPA, established in 1958, seeks to maintain the technological superiority of the US military by funding scientific investigations that span a wide range of activities, from laboratory efforts to the creation of full-scale technology demonstrations in such fields as biology, medicine, computer science, chemistry and physics. For further information about DARPA, please go to: www.darpa.mil About Sanofi Pasteur Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, offers the broadest range of vaccines, giving protection against 20 infectious diseases. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than €1 million in research and development. Sanofi Pasteur is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For further information about Sanofi Pasteur, please go to: www.sanofipasteur.com About In Cell Art In Cell Art, which is headquartered in Nantes (in western France), was founded in 2005 and is a member of the Atlanpole Biotherapies cluster of biotechnology excellence, also based in the west of France. In Cell Art is a privately held biopharmaceutical company specialising in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. With a Nobel Laureate amongst its founders and research team, the company has designed new classes of non-toxic vectors that are organised on a nanometric scale, enabling them to cross the cell barrier efficiently and safely. From these vectors, In Cell Art has developed a range of reagents and biotechnology-development services including ICANtibodies® and ICAFectin® transfection reagents, along with a pipeline of nanocarriers for the formulation and delivery of nucleic acid-based drugs. In the absence of recombinant antigens, ICANtibodies® allows, from an in silico antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed protein (including excreted, nuclear, cytoplasmic or membrane proteins). With ICANtibodies®, In Cell Art has assisted its clients in the production of more than 150 different functional antibodies, in less than two years. ICAFectin® transfection reagents are innovative synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections. This is demonstrated by their increasingly common use in studies published in leading journals including the Journal of Biological Chemistry, Nucleic Acids Research, PLoS ONE, PLoS Pathogens, Human Gene Therapy, Journal of Neurochemistry, Experimental Cell Research and Neoplasia. ICA614 nanocarrier, an innovative DNA synthetic formulation, offers unique, efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 nanocarrier represents a crucial step in DNA-vaccine development, and is currently being tested by major vaccine companies such as Sanofi Pasteur and Merial Ltd. With R&D programmes in oncology, in infectious diseases, and in cardiovascular diseases, In Cell Art has developed specific nanocarriers that allow efficient delivery of siRNA for the interference with the expression of targeted disease-associated genes. IN CELL ART works in partnership with, and grants research licences to, companies active in the development of RNAi therapeutic products. For further information about In Cell Art, please go to: www.incellart.com   Distribution Statement ‘A’ (Approved for Public Release, Distribution Unlimited)

Tirsdag den 15. november underskrev det danske innovationsnetværk DANSK LYS og den franske CLUSTER LUMIÈRE en samarbejdsaftale ved en reception på Den Franske Ambassade.  Frankrigs Ambassadør, Véronique Bujon-Barré, lykønskede parterne og udtrykte håb om at projektet må føre til nye muligheder for innovation og videreudvikling af de respektive nationale markeder for belysning.   Målet med aftalen er at danne et europæisk netværk European Lighting Cluster Alliance (ELCA) , som bl.a. skal øge viden og bevidsthed om lys, samt fremme udveksling af know-how på europæisk plan. Den officielle lancering af ELCA finder sted i Lyon den 7. – 8. december i forbindelse med konferencen ForumLED samt lysfesten ”Fête des Lumières”. Lysdesignere fra de to lande er som en første ”challenge” blev sat sammen i tværnationale grupper, som hen over de næste par måneder skal udvikle og præsentere et nyt koncept for belysning af henholdsvis Mozarts Plads og Christianshavns Torv i København. Københavns Kommune vil deltage i bedømmelsen af projekterne. Ambassadens Handelsafdeling, UBIFRANCE Danmark, følger det nye dansk-franske partnerskab tæt, og vil bistå parterne med råd og vejledning om handelsmæssige forhold. Vi formidler gerne kontakt til franske lysdesignere samt leverandører af belysnings-løsninger til såvel det offentlige rum, som til kontorer, butikker, industri m.m.

Frankrigs ledende producent af hospitalsinventar søger en samarbejdspartner på det danske marked Der tilbydes modulerbare elementer til ergonomisk, effektiv og hygiejnisk indretning af såvel operationsstue og sengeafsnit, som hospitalsapotek og lagerområde. Materialet er polypropylen + ABS plast + aluminium m. epoxy maling, hvilket sikrer maksimal hygiejne, da overfladen er fuldstændig uigennemtrængelig for bakterier. Kontakt venligst Annemette Jensen, tlf. 33 37 61 78 for yderligere oplysninger.

Til distribution i Danmark og Island, samt gerne resten af de nordiske lande, søges medico-distributør, som enten allerede har produkter til plastikkirurgi, eller som ønsker at udvide med denne produktgruppe.  Den franske producent garanterer produkter af højeste kvalitet – produceret på egen fabrik i Frankrig, hvor hvert enkelt implantat testes manuelt igennem hele produktionsprocessen. Implantater til bryst, ansigt, læg, balde, testikel, samt specialfremstillede implantater til særlige behov. Kontakt venligst Annemette Jensen, tlf. 33 37 61 78 for yderligere oplysninger.